Small Pharma Inc. (CVE:DMT – Get Free Report) shares fell 6.3% on Monday . The company traded as low as C$0.15 and last traded at C$0.15. 1,890,765 shares were traded during mid-day trading, an increase of 538% from the average session volume of 296,159 shares. The stock had previously closed at C$0.16.
Small Pharma Stock Performance
The business’s 50-day moving average is C$0.15 and its 200 day moving average is C$0.15. The company has a debt-to-equity ratio of 5.95, a quick ratio of 6.28 and a current ratio of 2.63. The company has a market cap of C$50.37 million, a PE ratio of -2.14 and a beta of 0.86.
Small Pharma Company Profile
Small Pharma Inc, a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage.
Recommended Stories
- Five stocks we like better than Small Pharma
- What is the S&P/TSX Index?
- 3 Buyable Stocks With Solid Bottoms Ready to Rebound
- The How And Why of Investing in Oil Stocks
- Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
- Top Stocks Investing in 5G Technology
- Robotaxi News: What Tesla and Lyft Headlines Mean for Shares
Receive News & Ratings for Small Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Small Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
